---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-25-000005"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:27:52.448825+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B

## Summary
- 2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.
- Q4 2024 revenue ~$13.5B, up 45% YoY, but $400M below low end of Oct 30 guidance due to slower incretin growth and lower channel inventory.
- Mounjaro Q4 revenue ~$3.5B, Zepbound ~$1.9B; non-incretin revenue grew 20% YoY.
- 2025 revenue guidance $58-61B, midpoint growth of 32% vs expected 2024; includes new product launches and manufacturing expansion.
- Full Q4 2024 results and 2025 financial guidance to be reported on February 6, 2025.

## SEC filing metadata
- accession: 0000059478-25-000005
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/0000059478-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947825000005/lly-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-25-000005
- JSON: https://secwatch.observer/filing/0000059478-25-000005.json
- Plain text: https://secwatch.observer/filing/0000059478-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.